Superpower peptides available for pre-order. Get first access.

Cosmetic and topical

Skin & aging

Nonapeptide-1

EvidenceLow research
ClassBrightening peptide

Key takeaway

Nonapeptide-1 is a synthetic nine-amino acid peptide, sold as Melanostatine, used in skincare as a brightening ingredient. Laboratory work suggests it blocks a hormone signal that tells pigment cells to make melanin, which is the basis for its use in products aimed at the appearance of dark spots and uneven tone. As of 2026, the evidence is essentially laboratory data and manufacturer claims, with no published human trial of the ingredient.

Published
October 5, 2026
Last updated
November 12, 2026

At a glance

What it isCosmetic ingredient, a peptide used for skin brightening
FDA statusDoes not require FDA approval, as a cosmetic ingredient rather than a drug
ResearchActivity supported by laboratory data and manufacturer claims; human trials are lacking
Used inProducts targeting the look of dark spots, hyperpigmentation, and dullness
Evidence strengthLow research

What is nonapeptide-1?

Nonapeptide-1 is a synthetic peptide of nine amino acids, marketed in skincare under the name Melanostatine (for example, Melanostatine-5). It is used as a brightening ingredient, intended to help with the appearance of dark spots and uneven skin tone rather than to bleach the skin. It is a cosmetic ingredient, not a drug.

How does it work?

Laboratory studies describe nonapeptide-1 as a blocker of a specific pigment signal. Pigment-producing cells, called melanocytes, make more melanin when a hormone known as alpha-MSH, which skin cells release after UV exposure1, binds to a receptor on their surface called MC1R. Nonapeptide-1 is designed to compete with alpha-MSH for that receptor, so the downstream signal to switch on melanin-making enzymes is dampened. In cell studies2, it has been used as a reference antagonist that reduces melanin production. The body has its own counter-signal: agouti signal protein also acts at MC1R, and in mouse pigment-cell studies it turned down dark-melanin production3. Nonapeptide-1's receptor route differs from the most common brightening approach, blocking tyrosinase4, the enzyme that makes melanin, which is how peptides such as decapeptide-12 work.

The practical idea is prevention more than correction: By quieting the signal that drives new pigment, it is positioned to limit the appearance of future dark spots rather than to strip away existing ones. These are laboratory findings, and in finished products the benefit is described in appearance terms, such as a brighter, more even-looking complexion.

Is it FDA-approved?

No, and it does not need to be. The FDA does not pre-approve cosmetic ingredients. A cosmetic may describe effects on the look of skin tone, while a claim to treat a pigmentation disorder would make a product a drug. Nonapeptide-1 is used as a cosmetic ingredient, for the appearance of the skin.

What is it used for?

Nonapeptide-1 is used in brightening serums and creams aimed at the look of dark spots, hyperpigmentation, and overall radiance. It is commonly combined with other brightening ingredients such as niacinamide or vitamin C and, in practice, is used alongside daily sun protection, since UV exposure drives pigmentation.

What does the research show?

The evidence is thin and mostly laboratory-based. According to PubMed, nonapeptide-1 appears in a cell study2 where it served as a known alpha-MSH blocker used for comparison, confirming anti-pigment activity in the lab. The manufacturer reports brightening activity in skin, but no corresponding independent, peer-reviewed human trial of the ingredient was found. So the brightening rationale is supported in principle by laboratory work but not by published human appearance trials.

What are the side effects?

Nonapeptide-1 is generally reported as well tolerated and non-irritating at cosmetic use levels, and it is positioned as a gentler alternative to some older brightening agents. Independent human safety data are limited, so a patch test is reasonable for sensitive skin.

More for skin & aging

Sources: a cell study using nonapeptide-1 as an alpha-MSH antagonist reference (Chen et al., Advances in Dermatology and Allergology, 2022, DOI: 10.5114/ada.2022.1158902), indexed on PubMed; reviews of alpha-MSH biology and tyrosinase-blocking brightening agents and a study of agouti signal protein (Dall'Olmo et al., Journal of Translational Medicine, 2023; Pillaiyar et al., Journal of Enzyme Inhibition and Medicinal Chemistry, 2017; Virador et al., Experimental Cell Research, 2000), indexed on PubMed; and manufacturer and cosmetic ingredient reference data on Melanostatine. This document is educational and does not constitute medical advice.